Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I trial of combretastatin a-4 phosphate with carboplatin.
Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. Bilenker JH, et al. Clin Cancer Res. 2005 Feb 15;11(4):1527-33. doi: 10.1158/1078-0432.CCR-04-1434. Clin Cancer Res. 2005. PMID: 15746056 Clinical Trial.
Phase II trial of sorafenib in advanced thyroid cancer.
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Gupta-Abramson V, et al. J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541894 Free PMC article. Clinical Trial.
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. Flaherty KT, et al. Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Sun W, Metz JM, Gallagher M, O'Dwyer PJ, Giantonio B, Whittington R, Haller DG. Sun W, et al. Cancer Chemother Pharmacol. 2011 Mar;67(3):621-7. doi: 10.1007/s00280-010-1365-2. Epub 2010 May 22. Cancer Chemother Pharmacol. 2011. PMID: 20495918 Clinical Trial.
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ. Sohal DP, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1485-91. doi: 10.1007/s00280-013-2147-4. Epub 2013 Mar 27. Cancer Chemother Pharmacol. 2013. PMID: 23532207 Clinical Trial.
537 results